{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-037065","form_type":"8-K","ticker":"NVNO","cik":"0001661053","company_name":"enVVeno Medical Corp","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.977190+00:00","generated_at":"2026-06-10T00:48:52.897856+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"enVVeno raises $28M in PIPE financing with milestone-based warrants","bullets":["Gross proceeds of $28M from sale of 3,844,704 shares, pre-funded warrants for 977,900 shares, and two tranches of warrants.","Tranche A warrants (4,822,604 shares) at $6.945, expire 30 days post SAVVE top-line data or Oct 2024.","Tranche B warrants (4,822,604 shares) at $8.334, expire 30 days post FDA PMA for VenoValve or Oct 2026.","Net proceeds ~$25.9M; funds for VenoValve and enVVe development and working capital.","Ladenburg Thalmann placement agent; 7% cash fee and warrants for 241,130 shares at $6.945."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-037065","json":"https://secwatch.observer/filing/0001493152-23-037065.json","markdown":"https://secwatch.observer/filing/0001493152-23-037065.md","text":"https://secwatch.observer/filing/0001493152-23-037065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661053/000149315223037065/0001493152-23-037065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661053/000149315223037065/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:48:52.897856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11928ecc81bd46b22656f77dd7fd3e5999532860","claim":"enVVeno Medical Corp entered into Registration Rights Agreement with certain institutional investors (effective 2023-10-06).","evidence_excerpt":"In connection with the offering, the Company and the Investors entered into a Registration Rights Agreement dated October 6, 2023 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and Warrant Shares.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661053/000149315223037065/0001493152-23-037065-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2023-10-06"}],"fact_type":"material_agreement"},{"claim_id":"decad42b67ebf8818bd0dedc7969788416e9a3c5","claim":"enVVeno Medical Corp entered into Securities Purchase Agreement with certain institutional investors valued at approximately $28 million (effective 2023-10-06).","evidence_excerpt":"On October 6, 2023, enVVeno Medical Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”) for the purpose of raising approximately $28 million in gross proceeds for the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661053/000149315223037065/0001493152-23-037065-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $28 million"},{"label":"Effective","value":"2023-10-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}